Mc Elhenny Sheffield Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History

Mc Elhenny Sheffield Capital Management, LLC

$303 Million
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 11, 2023	BUY	$285.76 - $321.48 $5,429 - $6,108	19 New	19 $0
Q1 2022 Apr 20, 2022	SELL	$221.42 - $260.97 $598,498 - $705,401	-2,703 Closed	0 $0
Q4 2021 Jan 12, 2022	BUY	$177.01 - $223.45 $19,294 - $24,356	109 Added 4.2%	2,703 $594,000
Q3 2021 Oct 12, 2021	BUY	$181.39 - $202.99 $470,525 - $526,556	2,594 New	2,594 $471,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Elhenny Sheffield Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mc Elhenny Sheffield Capital Management, LLC with notifications on news.

Account